Risk factors for medication-related osteonecrosis of the jaw and salivary IL-6 IN cancer patients

Risk Factors for Medication-Related Osteonecrosis of the Jaw—A Binomial Analysis of Data of Cancer Patients from Craiova and Constanta Treated with Zoledronic Acid

“…In other studies, the average duration of treatment with BF was between 12 and 55 months [61]. According to several studies, the duration of treatment with bisphosphonates of more than 10 doses was a significant risk factor for the occurrence of MRONJ in patients treated with zoledronic acid [27,39,62]. In the current study, the average duration of treatment with bisphosphonates was the highest in the 55-64 age group, followed by the older age groups (almost equal values-approx.…”

“…MRONJ appeared in a significantly higher percentage of patients from Craiova, who had a longer duration of treatment with BF (2 months longer on average). The duration of treatment with bisphosphonates is presented as the main risk factor for MRONJ in several studies [27,39,61,62]. In the present study, the median treatment duration was statistically significantly higher for the MRONJ group (24 months) than for the non-MRONJ group (12 months), p < 0.05.…”

“…Since MRONJ is a complication with a major negative impact on the quality of life of cancer patients [7,[37][38][39], a risk factors evaluation for each patient before the treatment initiation with bisphosphonates or other drugs to control bone metastases is necessary. In order to enable customized therapy for both bone metastases and oral diseases that may cause MRONJ lesions, it is advisable to establish an individual risk profile of the patient [27].…”

“…2 years of treatment), with the young age group having the shortest treatment period, under one and a half years. The duration of treatment with zoledronic acid is influenced by the bone metastases, the evolution of the underlying disease, and the duration of survival/healing of the patients [27,39,62]. Several studies have shown that patients treated with zoledronic acid or denosumab for more than 18 months have an increased risk of MRONJ recurrence and that the number of doses of zoledronic acid or denosumab administered, exposure to new chemotherapeutic compounds, and the type of cancer, are important factors in the risk of developing MRONJ [27,38,62].…”

Medication-Related Osteonecrosis of the Jaw in Patients Treated Concurrently with Antiresorptive and Antiangiogenic Agents: Systematic Review and Meta-Analysis

“…From the 25 studies that were included for full-text analysis, 14 were excluded; six studies only reported a single arm MRONJ case series or a case control study from which prevalence could not be assessed, [32][33][34][35][36][37] seven studies did not include/specify any AA therapy, [38][39][40][41][42][43][44] and one record was a conference abstract for which a full text was included from the original search. [45] Finally, a total of 11 full texts with extractable data were included in the qualitative and quantitative syntheses.…”